About Cyclerion Therapeutics

Cyclerion Therapeutics develops pharmacological treatments utilizing soluble guanylate cyclase (sGC) to target serious diseases associated with unmet medical needs. The company employs a strategic approach to drug development, leveraging cross-disciplinary expertise and collaborations to enhance patient access to its therapies.

```xml <problem> Treatment-resistant depression (TRD) presents a significant challenge in mental healthcare, as conventional treatments often fail to provide adequate relief for affected individuals. The limitations of existing therapies highlight the urgent need for innovative approaches that can address the unique needs of patients with TRD. </problem> <solution> Cyclerion Therapeutics is a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) diseases, with an initial focus on treatment-resistant depression (TRD). The company is pursuing an individualized therapy for TRD, delivering generic intravenous anesthetics via a personalized delivery device that uses biofeedback for optimal safety and efficacy. This approach leverages well-established medicines with extensive safety data and cutting-edge technologies to enhance treatment precision. Cyclerion's strategy involves identifying and developing therapeutics that target neuropsychiatric disorders beyond conventional approaches, with the goal of bringing safe, effective, and accessible solutions to patients faster and at a lower cost. </solution> <features> - Personalized delivery device for intravenous anesthetics, utilizing biofeedback for safety and efficacy - Focus on neuropsychiatric disorders, starting with treatment-resistant depression (TRD) - Leveraging well-established medicines with extensive safety data - Application of cutting-edge technologies to enhance treatment precision and effectiveness - Option agreement to negotiate access to key intellectual property for TRD treatment </features> <target_audience> The primary target audience includes individuals suffering from treatment-resistant depression (TRD) and the healthcare providers who treat them, including psychiatrists and other mental health professionals. </target_audience> ```

What does Cyclerion Therapeutics do?

Where is Cyclerion Therapeutics located?

Cyclerion Therapeutics is based in Cambridge, United Kingdom.

When was Cyclerion Therapeutics founded?

Cyclerion Therapeutics was founded in 2019.

How much funding has Cyclerion Therapeutics raised?

Cyclerion Therapeutics has raised 5000000.

Location

Cambridge, United Kingdom

Founded

2019

Funding

5000000

Employees

12 employees

Major Investors

Peter M. Hecht

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Cyclerion Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

cyclerion.com 3K+

Crunchbase

Founded 2019 – Cambridge, United Kingdom

Funding

Estimated Funding

$5M+

Major Investors

Peter M. Hecht

Team (10+)

No team information available.

Company Description

Problem

Treatment-resistant depression (TRD) presents a significant challenge in mental healthcare, as conventional treatments often fail to provide adequate relief for affected individuals. The limitations of existing therapies highlight the urgent need for innovative approaches that can address the unique needs of patients with TRD.

Solution

Cyclerion Therapeutics is a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) diseases, with an initial focus on treatment-resistant depression (TRD). The company is pursuing an individualized therapy for TRD, delivering generic intravenous anesthetics via a personalized delivery device that uses biofeedback for optimal safety and efficacy. This approach leverages well-established medicines with extensive safety data and cutting-edge technologies to enhance treatment precision. Cyclerion's strategy involves identifying and developing therapeutics that target neuropsychiatric disorders beyond conventional approaches, with the goal of bringing safe, effective, and accessible solutions to patients faster and at a lower cost.

Features

Personalized delivery device for intravenous anesthetics, utilizing biofeedback for safety and efficacy

Focus on neuropsychiatric disorders, starting with treatment-resistant depression (TRD)

Leveraging well-established medicines with extensive safety data

Application of cutting-edge technologies to enhance treatment precision and effectiveness

Option agreement to negotiate access to key intellectual property for TRD treatment

Target Audience

The primary target audience includes individuals suffering from treatment-resistant depression (TRD) and the healthcare providers who treat them, including psychiatrists and other mental health professionals.